A partnership between Alphabet’s Verily and OneOncology aims to improve the efficiency of cancer clinical trials, through the adoption of Verily’s SignalPath clinical trial management software across the OneOncology Research Network, which the companies said would help improve systems infrastructure, streamline regulatory processes and enhance collaboration with sponsors. They also hope to expand research opportunities across community oncology centers and potentially increase participation in trials, citing research showing that there are more than 1,300 cancer drugs in the pipeline, but also that participation rates in the US among adults with cancers is only 5%.
Still, studies have shown that there are a number of barriers that get in the way of expanding clinical trials to community cancer centers beyond the academic cancer centers where many of them take place